Get the Stockscreener App
4.87
8.46%
-0.45
After Hours:
4.89
0.02
+0.41%
Eyepoint Inc stock is traded at $4.87, with a volume of 4.12M.
It is down -8.46% in the last 24 hours and down -60.05% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$5.32
Open:
$5.17
24h Volume:
4.12M
Relative Volume:
1.48
Market Cap:
$419.85M
Revenue:
$7.62M
Net Income/Loss:
$-271.60M
P/E Ratio:
-1.3907
EPS:
-3.5018
Net Cash Flow:
$-271.54M
1W Performance:
+0.00%
1M Performance:
-60.05%
6M Performance:
-71.44%
1Y Performance:
-58.83%
1-Day Range:
$4.87
$5.35
1-Week Range:
$4.7032
$6.345
52-Week Range:
$3.95
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
4.87 | 465.55M | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70% - The Economic Times
Taxes of EyePoint, Inc. – HAM:PV3B - TradingView
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) - Business Wire
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals - PR Newswire
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Stocktwits
EyePoint's Wet AMD Drug Duravyu Fails Key Late-Stage Trial - Medical Dialogues
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's Why - MarketBeat
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown (NASDAQ:EYPT) - Seeking Alpha
EyePoint: Still A Sell After Phase 3 Crash (NASDAQ:EYPT) - Seeking Alpha
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold" - MarketBeat
These Analysts Slash Their Forecasts On EyePoint - Sahm
EyePoint director Karen L. Zaderej buys $52,258 in stock - Investing.com South Africa
EyePoint director Karen Zaderej reports purchase of 10,600 shares worth $52,258 - Bitget
EyePoint (EYPT) Insider Karen Zaderej Buys 10,600 Shares, Signaling Confidence - GuruFocus
EyePoint Director Karen Zaderej Acquires 10,600 Shares in Open-Market Transaction - Kalkine Media
EyePoint director Karen L. Zaderej buys $52,258 in stock By Investing.com - Investing.com Australia
EyePoint (EYPT) director adds to stake in open‑market buy - Stock Titan
EyePoint IncInterim Phase 3 Data Shows Con - Moomoo
EYPT Maintains Buy Rating by Citigroup -- Price Target Lowered to $17.00 - GuruFocus
EyePoint Inc. (EYPT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
EYPT Stock Crashes On Duravyu Data But Catalysts Loom - StocksToTrade
Traders Buy Large Volume of Call Options on Eyepoint Pharmaceuticals (NASDAQ:EYPT) - MarketBeat
EYPT Looks 1359.7% Overvalued on GF Value™ - GuruFocus
Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
EYEPOINT INC : CITIGROUP CUTS TARGET PRICE TO $17 FROM $35 - Moomoo
EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says - marketscreener.com
EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYUSlideshow - Seeking Alpha
EyePoint’s Duravyu falls short to Eylea in Phase III trial - Yahoo Finance
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal - TradingView
EyePoint rebounds despite multiple downgrades (EYPT:NASDAQ) - Seeking Alpha
RBC Capital cuts EyePoint stock rating on trial miss By Investing.com - Investing.com Australia
Chardan downgrades EyePoint stock rating on regulatory concerns By Investing.com - Investing.com South Africa
Chardan downgrades EyePoint stock rating on regulatory concerns - Investing.com Nigeria
Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more - STAT
EYPT Downgraded by Chardan Capital -- Price Target Lowered to $5.00 - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Chardan Capital to Neutral - MarketBeat
Eyepoint Pharmaceuticals' (EYPT) Sector Perform Rating Reiterated at Royal Bank Of Canada - MarketBeat
EYPT Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Earns Neutral Rating from HC Wainwright - MarketBeat
Chardan Downgrades EyePoint Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $65 - marketscreener.com
EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’ - TradingView
Dow Falls 150 Points; NY Empire State Manufacturing Index Rises In August - Sahm
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Sahm
EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study - Sahm
Why Is Ocular Therapeutix Stock Gaining Monday? - Sahm
RBC Downgrades EyePoint to Sector Perform From Outperform, Cuts Price Target to $5 From $37, Keeps Speculative Risk - marketscreener.com
HC Wainwright Downgrades EyePoint Pharmaceuticals to Neutral From Buy - marketscreener.com
EyePoint (EYPT) Following LUGANO Data Is The Undervalued Narrative Still Intact - simplywall.st
RBC Capital cuts EyePoint stock rating on trial miss - Investing.com
Guggenheim reiterates Buy on EyePoint stock after mixed trial data By Investing.com - Investing.com South Africa
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank - pharma.economictimes.indiatimes.com
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):